Saltar al contenido

HCA Florida North Florida Hospital announces launch of new Blood Cancer and Bone Marrow Transplant and Cellular Therapy Program

First transplant program of its kind in HCA Florida Healthcare

August 13, 2024
Exterior image of HCA Florida North Florida Hospital

HCA Florida North Florida Hospital announced today that the hospital will launch the Sarah Cannon Transplant and Cellular Therapy (TCT) Program by the end of 2024. This program will be part of the HCA Healthcare Sarah Cannon Cancer Network representing a comprehensive, national network of cancer professionals working in tandem in the pursuit of high quality, innovative, research-backed cancer care close to home.  

“This new program is a tremendous milestone for our oncology program, our hospital and our community,” said C. Eric Lawson, chief executive officer of HCA Florida North Florida Hospital. “By providing these highly-specialized and innovative services, we can provide patients with these complex cancers the ability to stay close to home to receive treatment, instead of having to seek treatment elsewhere across the state or nation. Our program will not only treat patients in north central Florida, but in the southeast United States, creating healthier tomorrows for all.” 

The Sarah Cannon Transplant and Cellular Therapy Program at HCA Florida North Florida Hospital will be one of 10 Sarah Cannon Transplant and Cellular Therapy Network programs in HCA Healthcare and the first in HCA Florida Healthcare. This program will bring more complex care to the hospital’s campus, including an intermediate care inpatient oncology unit, apheresis and infusion services, and a cellular therapy laboratory. Sarah Cannon Research Institute (SCRI) will be developing an early and late phase blood cancer and TCT clinical research program on-site.

The program will launch with a phased approach starting in Q4 of 2024 and will provide acute leukemia care, autologous hematopoietic cell transplantation (HCT), cellular therapy including chimeric antigen receptor T-cell therapy (CAR T) and allogeneic hematopoietic cell transplantation (HCT). To learn more about our oncology services, visit HCAFloridaHealthcare.com.

Publicado:
August 13, 2024
:
HCA Florida North Florida Hospital

Artículos relacionados con la sala de prensa


First robotic Whipple procedure performed at HCA Florida North Florida Hospital 

July 03, 2024
New minimally invasive surgical option for gastrointestinal cancers.

First robotic Whipple procedure performed at HCA Florida North Florida Hospital 

July 03, 2024
New minimally invasive surgical option for gastrointestinal cancers.

NFH Launches Hepatic Artery Infusion Program, first in North Central Florida 

November 16, 2023
This innovative treatment gives patients with stage 4 colorectal cancer with unresectable liver metastasis a new option to improve their survival and enable future surgery for removal of liver metastasis.